The content on this site is intended for healthcare professionals only
Dr Castillo speaks with ecancer at EHA 23 about results from a prospective phase II study of venetoclax in previously treated Waldenström Macroglobulinemia (WM).
He describes the over expression of BCL2 in these cells, and the encouraging responses of a 90% response in IGM levels and reduction in blood marrow.
With venetoclax being well tolerated, Dr Castillo outlines future combinations and trial validation with larger patient cohorts.
For more in WM, watch Prof Meletios Dimopolous discuss the use of ibrutinib with chemotherapy in the iNNOVATE trial here.
Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma
New classification for identifying HR myeloma based on cytogenetic abnormalities
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Advancing breast cancer treatment in Uganda by improving molecular testing
Somatic mutation profile of breast cancer in Uganda
